Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. Br J Clin Pharmacol. 2011;71:522–7. https://doi.org/10.1111/j.1365-2125.2010.03845.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abraham J, Montero AJ, Jankowitz RC, Salkeni MA, Beumer JH, Kiesel BF, Piette F, Adamson LM, Nagy RJ, Lanman RB, et al. Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER2-Positive breast Cancer: NSABP Foundation Trial FB-10. J Clin Oncol. 2019;37:2601–9. https://doi.org/10.1200/JCO.19.00858.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aleanizy FS, Alqahtani FY, Seto S, Al Khalil N, Aleshaiwi L, Alghamdi M, Alquadeib B, Alkahtani H, Aldarwesh A, Alqahtani QH, et al. Trastuzumab targeted Neratinib loaded poly-amidoamine dendrimer nanocapsules for breast Cancer therapy. Int J Nanomedicine. 2020;15:5433–43. https://doi.org/10.2147/IJN.S256898.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aljakouch K, Lechtonen T, Yosef HK, Hammoud MK, Alsaidi W, Kotting C, Mugge C, Kourist R, El-Mashtoly SF, Gerwert K. Raman Microspectroscopic evidence for the metabolism of a tyrosine kinase inhibitor, Neratinib, in Cancer cells. Angew Chem Int Ed Engl. 2018;57:7250–4. https://doi.org/10.1002/anie.201803394.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alkhezayem S, Wani TA, Wakil S, Aljuraysi A, Zargar S. Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib. Saudi Pharm J. 2020;28:963–70. https://doi.org/10.1016/j.jsps.2020.06.017.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Dieras V, Hershman DL, Agrapart V, Ananthakrishnan R, Staroslawska E. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013;24:109–16. https://doi.org/10.1093/annonc/mds284.

Article  CAS  PubMed  Google Scholar 

Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, et al. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in previously untreated metastatic ERBB2-Positive breast Cancer: the NEfERT-T Randomized Clinical Trial. JAMA Oncol. 2016;2:1557–64. https://doi.org/10.1001/jamaoncol.2016.0237.

Article  PubMed  Google Scholar 

Ban M, Mise P, B., and, Vrdoljak E. Early HER2-Positive breast Cancer: current treatment and novel approaches. Breast Care (Basel). 2020;15:560–9. https://doi.org/10.1159/000511883.

Article  PubMed  Google Scholar 

Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, Brufsky A, Litvak A, Ibrahim E, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol. 2020;31:1223–30. https://doi.org/10.1016/j.annonc.2020.05.012.

Article  CAS  PubMed  Google Scholar 

Baselga J, Coleman RE, Cortes J, Janni W. Advances in the management of HER2-positive early breast cancer. Crit Rev Oncol Hematol. 2017;119:113–22. https://doi.org/10.1016/j.critrevonc.2017.10.001.

Article  PubMed  PubMed Central  Google Scholar 

Bilancia D, Rosati G, Dinota A, Germano D, Romano R, Manzione L. Lapatinib in breast cancer. Ann Oncol. 2007;18(Suppl 6):vi26–30. https://doi.org/10.1093/annonc/mdm220.

Article  PubMed  Google Scholar 

Booth L, Roberts JL, Avogadri-Connors F, Cutler RE Jr., Lalani AS, Poklepovic A, Dent P. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. Cancer Biol Ther. 2018;19:239–47. https://doi.org/10.1080/15384047.2018.1423927.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borges VF, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I, Welch S, Conlin A, Chaves J, Bedard PL, et al. Tucatinib Combined with Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive metastatic breast Cancer: a phase 1b clinical trial. JAMA Oncol. 2018;4:1214–20. https://doi.org/10.1001/jamaoncol.2018.1812.

Article  PubMed  Google Scholar 

Bose R, Ma CX. Breast Cancer, HER2 mutations, and overcoming Drug Resistance. N Engl J Med. 2021;385:1241–3. https://doi.org/10.1056/NEJMcibr2110552.

Article  PubMed  Google Scholar 

Bradley CA. Brain metastases respond to neratinib plus capecitabine. Nat Rev Clin Oncol. 2019;16:336. https://doi.org/10.1038/s41571-019-0207-3.

Article  CAS  PubMed  Google Scholar 

Bredin P, Walshe JM, Denduluri N. Systemic therapy for metastatic HER2-positive breast cancer. Semin Oncol. 2020;47:259–69. https://doi.org/10.1053/j.seminoncol.2020.07.008.

Article  CAS  PubMed  Google Scholar 

Breslin S, Lowry MC, O’Driscoll L. Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4. Br J Cancer. 2017;116:620–5. https://doi.org/10.1038/bjc.2016.445.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, Schwartz G, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28:1301–7. https://doi.org/10.1200/JCO.2009.25.8707.

Article  CAS  PubMed  Google Scholar 

Cesca MG, Vian L, Cristovao-Ferreira S, Ponde N, de Azambuja E. HER2-positive advanced breast cancer treatment in 2020. Cancer Treat Rev. 2020;88:102033. https://doi.org/10.1016/j.ctrv.2020.102033.

Article  CAS  PubMed  Google Scholar 

Chan A. Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness. Ther Adv Med Oncol. 2016;8:339–50. https://doi.org/10.1177/1758834016656494.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:367–77. https://doi.org/10.1016/S1470-2045(15)00551-3.

Article  CAS  PubMed  Google Scholar 

Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, et al. Final efficacy results of Neratinib in HER2-positive hormone receptor-positive early-stage breast Cancer from the Phase III ExteNET Trial. Clin Breast Cancer. 2021;21:80–91e87. https://doi.org/10.1016/j.clbc.2020.09.014.

Article  CAS  PubMed  Google Scholar 

Chia SKL, Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Mansi J, Barrios CH, et al. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. Breast Cancer Res. 2019;21:39. https://doi.org/10.1186/s13058-019-1115-2.

Article  PubMed  PubMed Central  Google Scholar 

Chila G, Guarini V, Galizia D, Geuna E, Montemurro F. The clinical efficacy and safety of Neratinib in Combination with Capecitabine for the treatment of adult patients with Advanced or metastatic HER2-Positive breast Cancer. Drug Des Devel Ther. 2021;15:2711–20. https://doi.org/10.2147/DDDT.S281599.

Article  PubMed  PubMed Central  Google Scholar 

Chow LW, Xu B, Gupta S, Freyman A, Zhao Y, Abbas R, Vo Van ML, Bondarenko I. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer. 2013;108:1985–93. https://doi.org/10.1038/bjc.2013.178.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, et al. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Sci Signal. 2018;11. https://doi.org/10.1126/scisignal.aat9773.

Collins DM, Conlon NT, Kannan S, Verma CS, Eli LD, Lalani AS, Crown J. Preclinical characteristics of the irreversible Pan-HER kinase inhibitor Neratinib compared with Lapatinib: implications for the treatment of HER2-Positive and HER2-Mutated breast Cancer. Cancers (Basel). 2019;11. https://doi.org/10.3390/cancers11060737.

Collins DM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C, Davies AM, Mahgoub T, et al. Effects of HER Family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast Cancer. Clin Cancer Res. 2021;27:807–18. https://doi.org/10.1158/1078-0432.CCR-20-2007.

Article  CAS  PubMed  Google Scholar 

Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, O’Driscoll L. miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer. 2014;13. https://doi.org/10.1186/1476-4598-13-71.

Corti C, Antonarelli G, Criscitiello C, Lin NU, Carey LA, Cortes J, Poortmans P, Curigliano G. Targeting brain metastases in breast cancer. Cancer Treat Rev. 2022;103:102324. https://doi.org/10.1016/j.ctrv.2021.102324.

Article  CAS  PubMed  Google Scholar 

Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, et al. Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast Cancer. Clin Cancer Res. 2019;25:277–89. https://doi.org/10.1158/1078-0432.CCR-18-1544.

Article  CAS  PubMed  Google Scholar 

Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2 + metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33:321–9. https://doi.org/10.1016/j.annonc.2021.12.005.

Article  CAS  PubMed  Google Scholar 

Dai MS, Feng YH, Chen SW, Masuda N, Yau T, Chen ST, Lu YS, Yap YS, Ang PCS, Chu SC, et al. Analysis of the pan-asian subgroup of patients in the NALA Trial: a randomized phase III NALA trial comparing neratinib + capecitabine (N + C) vs lapatinib + capecitabine (L + C) in patients with HER2 + metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. Breast Cancer Res Treat. 2021;189:665–76.